Neurotoxins with enhanced target specificity

Details Neurotoxins with enhanced target specificity Neurotoxins with enhanced target specificity

2007-09-25

2007-09-25

Navarro, Mark (Department: 1645)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C530S350000, C424S234100

Reexamination Certificate

active

09726949

ABSTRACT:
Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.

REFERENCES:
patent: 5562907 (1996-10-01), Arnon
patent: 5728399 (1998-03-01), Wu et al.
patent: 5763250 (1998-06-01), Williams et al.
patent: 5837265 (1998-11-01), Montal et al.
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6022950 (2000-02-01), Murphy
patent: 6051239 (2000-04-01), Simpson et al.
patent: 6066621 (2000-05-01), Sela et al.
patent: 6087327 (2000-07-01), Pearce et al.
patent: 6113946 (2000-09-01), Szoka et al.
patent: 6203794 (2001-03-01), Dolly et al.
patent: 6221355 (2001-04-01), Dowdy
patent: 6261572 (2001-07-01), Donovan
patent: 6312708 (2001-11-01), Donovan
patent: 6333303 (2001-12-01), Borgford
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6361938 (2002-03-01), O'Mahony et al.
patent: 6383775 (2002-05-01), Duff et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6416959 (2002-07-01), Giuliano
patent: 6426075 (2002-07-01), Fitzgerald et al.
patent: 6444209 (2002-09-01), Johnson et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6641820 (2003-11-01), Donovan
patent: 6670147 (2003-12-01), Heidtmann et al.
patent: 6776990 (2004-08-01), Sachs et al.
patent: 6787517 (2004-09-01), Gil et al.
patent: 2002/0045208 (2002-04-01), Eck et al.
patent: 2002/0177545 (2002-11-01), Donovan
patent: 95/32738 (1995-12-01), None
patent: 98/07864 (1998-02-01), None
patent: 98/20135 (1998-05-01), None
patent: 00/61768 (2000-10-01), None
patent: 01/14570 (2001-03-01), None
Chaddock et al, Infection and Inmmunity, vol. 68(5), pp. 2587-2593, May 2000.
Zhou et al, Biochemistry, vol. 34(46), pp. 15175-15181, 1995.
Aoki et al, Eur. J. Neurol., vol. 6(suppl 4), pp. S3-S10, 1999.
Carter, Chapter 13, Site specific proteolysis of Fusion proteins, pp. 181-193, American Chemical Society, 1990, In Protein Purification: From Molecular Mechanisms to Large Scale Processes.
Niemann et al, 1994, Trends in Cell Biology, vol. 4, pp. 179-185.
O'hare, Mary et al, FEBS, vol. 273(1-2), pp. 200-204, Oct. 1990.
Robinson, JP et al, Journal of Biological Chemistry, vol. 250(18), pp. 7435-7442, Sep. 25, 1975.
Woody, MA et al, Toxicon, vol. 27(10), pp. 1143-1150, 1989.
Yan, Li et al, Biochemistry, 1994, vol. 33(22), pp. 7014-7020.
Montecucco, C et al, Trends in biochemistry, vol. 18, 1993, pp. 324-327.
Walker, PA et al, Bio/Technology, vol. 12, Jun. 1994, pp. 601-605.
Demotz, S et al, Journal of Immunological Methods, Aug. 1989, vol. 122(1), pp. 67-72, A novel and simple procedure for determining T cell epitopes in protein antigens. (tetanus toxin examplified).
Shone, CC et al, European Journal of Biochemistry, vol. 217, pp. 965-971, Nov. 1993, Proteolytic cleavage of synthetic fragments of vesicle associated membrane isoform-2 by botulinum type B neurotoxin.
Shone, CC et al, European Journal of Biochemistry, FEBS (Germany, West) Aug. 15, 1985, vol. 151(1), pp. 75-82, abstract only.
Kistner, A et al,Naunyn-Schmiedeberg's archives of pharmacology (Germany), Feb. 1992, vol. 345 (2), pp. 227-234, (abstract only).
Chaddock, JA et al, Infection and Immunity, May 2000, vol. 68(5), pp. 2587-2593.
Aravamudan, B et al, Journal of Neurobiology, vol. 54, pp. 417-438, 2003.
Bryant, NJ et al, The EMBO Journal, vol. 20, pp. 3380-3388, 2001.
Hayashi, Y et al, Plant and Cell physiology (Japan), Sep. 2001, vol. 42(9), pp. 894-899 (abstract only).
Flaumenhaft, Robert, Arteriosclerosis, thrombosis and vascular biology (United States) Jul. 1, 2003, vol. 23(7), pp. 1152-1160 (abstract only).
Ernst, Joel D, Cellular Microbiology, vol. 2(5) pp. 379-386, 2000.
Agarwal, R et al, Biochemistry 2004, vol. 43, pp. 6637-6644, Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Gul 212-Gln reveals the pivotal role of the Glu 212 carboxylate in the catalytic pathway.
Das Gupta et al (1972), vol. 6(4), Infection and Immunity, pp. 587-590, Oct., Role of protease in Natural activation of Clostridium botulinum neurotoxin.
Redondo, Pedro C. et al (2004) J. Physiol., vol. 558(1), pp. 99-107 , A role for SNAP-25 but not VAMPs in sore-mediated Ca2+ entry in human platelets.
Vandederckhove, J et al, FEBS Letters, Dec. 10, 1987; vol. 225 (1-2) pp. 48-52, Clostridium perfringesn iota toxin ADP-ribosylates skeletal muscle actin in Arg-177 (abstract only).
Borodic, et al. “Pharmacology and Histology of the Therapeutic Application of Botulinum Toxin,”In Therapy with Botulinum Toxin(Jankovic J. & Hallett, eds 1994), pp. 119-157.
Li Yan et al, “Expression and characterization of the heavy chain of tetanus toxin: Reconstitution of the fully-recombinant dichain protein in the active form”, Journal of Biochemistry, vol. 125, No. 6, Jun. 1999, pp. 1200-1208.
Ashton Anthony et al, “Tetanus toxin inhibits neuroexocytosis even when its Zn-2+-dependent protease activity is removed”, Journal of Biological Chemistry, vol. 270, No. 52, 1995, pp. 31386-31390.

Affiliated with

Also associated with

Rating

Neurotoxins with enhanced target specificity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neurotoxins with enhanced target specificity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurotoxins with enhanced target specificity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3800625